A two-compartment switch for a SEC cargo: nucleolar retention versus AFF4-induced nucleoplasmic droplets, set by one methylated arginine
also called Tat PRMT2 nucleolar exit · AFF4 SEC droplets · SEC compartment switch
HIV's Tat protein can either be parked in the nucleolus or pulled into liquid droplets built by the elongation machinery in the rest of the nucleus, and a single chemical mark on one amino acid decides which. It is the clearest worked example of a protein's job being decided by which nuclear compartment holds it.
The same thing, for a scientist
In HIV-1 latency, Tat's transcriptional activity is **oppositely regulated by NPM1-mediated nucleolar retention and AFF4-induced phase separation in the nucleoplasm**; PRMT2 methylates Tat arginine 52 to reinforce nucleolar sequestration while counteracting incorporation into SEC droplets, inactivating Tat and promoting proviral latency [E1]. This is not a leukaemia result and Tat is not a KMT2A fusion, but it is the only system in which a SEC-associated cargo has a measured, reversible, two-compartment choice with a defined chemical switch and a transcriptional readout, and it bears on three things this graph holds separately. First, the **nucleolus is the one compartment with direct published images of a KMT2A fusion inside it**, and this graph has treated that as a curiosity; here nucleolar residence is the *off* state for a SEC cargo. Second, AFF4 - the paralogue of AFF1 - is the component that builds the droplets, which is the closest the SEC literature comes to an AFF-family phase-separation function. Third, the switch is a single post-translational modification, and this graph's phosphosite work has found that none of the 46 mapped patient phosphosites in these proteins sits in a folded domain, i.e. they sit exactly where a switch of this kind would sit. The comparator's value is that it makes 'which compartment holds the fusion' a testable functional question rather than a descriptive one.
What transfers and what does not
Transfers. The architecture: a cargo with two mutually exclusive nuclear destinations, one inert and one active, arbitrated by a modification on a single residue, with the active destination being an AFF-family-built condensate. That architecture is testable for a KMT2A fusion and nobody has tested it.
Does not transfer. Tat is a small viral protein with no chromatin-binding module. KMT2A::AFF1 is a 2,000-plus-residue chimera anchored by CXXC, AT-hooks, menin and LEDGF, and its compartment is unlikely to be arbitrated by a single residue when it has four independent chromatin tethers. The honest reading is that the Tat switch is a model of how a compartment choice can be functional, not a prediction about the fusion.
And the assay caution applies. The droplet half of the claim rests on the standard condensate assay set, which cannot distinguish phase separation from binding to spatially clustered sites 2, and hexanediol in a chromatin context does something close to the opposite of what the assay assumes 3.
The specific prediction it licenses for KMT2A fusions
This graph records that a KMT2A fusion has been photographed in the nucleolus by two independent groups twenty-two years apart, and that the second found a nucleolar stress response. It also records the EWSR1::FLI1 comparator, in which deliberately dragging the fusion into the nucleolus stops it driving cancer at all.
Two independent systems - a viral SEC cargo and a Ewing sarcoma fusion - therefore agree that the nucleolus is an inactivating destination for a transcriptional driver. If that generalises, nucleolar KMT2A fusion is not a functional pool but a sink, and the fraction of fusion protein in the nucleolus is a quantity worth measuring rather than a picture worth showing.
The measurement is a nucleolar fractionation and a blot - the same size-dimension route this beat proposes throughout - and it would convert a twenty-two-year-old image into a number.
| system | HIV-1 latency, cell-line models and patient CD4+ T cells |
|---|---|
| switch | PRMT2 methylation of Tat R52 |
| retention factor | NPM1 |
| droplet factor | AFF4 |
| transfers to kmt2a | architecture only, not the residue-level mechanism |
compartments
[ "nucleolus (inactive)", "nucleoplasmic SEC droplets (active)" ]
- If nucleolar sequestration inactivates a transcriptional driver, a therapeutic that forced the fusion into the nucleolus would have to overcome four independent chromatin tethers that Tat does not have.
- A methylation-based compartment switch would be drugged with a PRMT inhibitor class already in leukaemia trials for other reasons, so an unrecognised compartment effect could confound those readouts in KMT2A-rearranged patients.
- What fraction of KMT2A::AFF1 is nucleolar in a t(4;11) cell, measured by nucleolar fractionation and blot rather than by an image?
- Is nucleolar residence an inactivating sink for KMT2A fusions, as it is for Tat and as forced nucleolar targeting showed for EWSR1::FLI1?
- Does any mapped patient modification on AFF1 or KMT2A sit at a position that could act as a compartment switch?
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
The transcriptional activity of HIV-1 Tat is oppositely regulated by NPM1-mediated nucleolar retention and AFF4-induced phase separation in the nucleoplasm, and PRMT2 preferentially methylates Tat arginine 52 to reinforce nucleolar sequestration while counteracting incorporation into SEC droplets, inactivating Tat and promoting proviral latency in cell-line latency models and in HIV-1-infected patient CD4+ T cells.
PRMT2 promotes HIV-1 latency by preventing nucleolar exit and phase separation of Tat into the Super Elongation Complex · Jin J, et al. · Nature communications 2023What this evidence cannot show
HIV latency, not leukaemia; Tat is a small viral protein with no chromatin-binding module and no fusion partner. The droplet observations use the standard condensate assay set whose limits are recorded elsewhere in this graph. AFF4 is the SEC scaffold, not AFF1, and the two are not interchangeable in the fusion context.
Evidence that argues against this (1)
- At physiological expression, low-complexity-domain interactions that control transcription form dynamic hubs without detectable phase separation, so the 'SEC droplet' compartment may be a concentration-dependent description of a hub rather than a phase. Chong S et al. 2018
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
1,6-hexanediol sensitivity and classical FRAP recovery both fail to distinguish liquid-liquid phase separation from binding to spatially clustered sites; only model-free calibrated half-bleaching discriminates them.
Detecting and quantifying liquid-liquid phase separation in living cells by model-free calibrated half-bleaching · Muzzopappa F, et al. · Nature communications 2022What this evidence cannot show
A methods paper in model systems, applied here as an interpretive constraint on the droplet half of the Tat result.
Evidence that argues against this (1)
- Clustered-site binding predicts sequence-specific targeting where phase separation predicts bulk enrichment, so the rival model makes sharper predictions and is not a null result. Chong S et al. 2018
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
1,6-hexanediol rapidly immobilises and condenses chromatin in living human cells, distinct from melting a droplet, and the authors instruct readers to use this in reinterpreting chromatin-associated droplet results.
1,6-hexanediol rapidly immobilizes and condenses chromatin in living human cells · Itoh Y, et al. · Life science alliance 2021What this evidence cannot show
The nucleolus is itself a condensate and the nucleolar half of the Tat result does not depend on hexanediol, so this constrains one half of the claim and not the other.
Evidence that argues against this (1)
- Nucleolar retention in the Tat system is established by NPM1 dependence and by a methylation-site mutant rather than by a chemical droplet probe, so that half of the architecture stands independently of the hexanediol critique. Jin J et al. 2023
the reservoir-facing half of the same Tat comparison
HEXIM1 is the inhibitory half of the 7SK reservoir this node's SEC-droplet argument depends on, and its nucleoplasmic behaviour is measured as subdiffusion set by 7SK and P-TEFb binding rather than as residence in a droplet
AFF4 builds the nucleoplasmic SEC compartment that pulls Tat out of the nucleolus
COMPARTMENT OBJECTION TO THIS ENTRY'S OWN HYPOTHESIS, not previously raised: extracting P-TEFb from the 7SK snRNP and handing it to AF4/AF4N requires DDX6 in the nucleus at the 7SK particle, yet DDX6's constitutive address is the cytoplasmic P-body and its nuclear entry is a 4E-T-dependent piggy-back. The 2016 report measures no compartment (Q93 2026-09-21)
- analogous to →The nucleolus — the one compartment with direct published images of a KMT2A fusion inside it
in two independent systems the nucleolus is the inactivating destination for a transcriptional driver
a second system in which forcing a driver into the nucleolus switches it off
AFF4 is the SEC component that builds the active-state droplets in this system
Tat's transactivation runs through P-TEFb within the SEC, the complex whose droplets are the active compartment
the AFF-family droplet function is documented for AFF4 and for no other family member